A phase 1 study of ABT-869 in patients withrefractory or relapsed acute myelogenous leukaemia or myelodysplastic syndrome

Trial Profile

A phase 1 study of ABT-869 in patients withrefractory or relapsed acute myelogenous leukaemia or myelodysplastic syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2006

At a glance

  • Drugs Cytarabine; Linifanib
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top